Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Duvelisib Approved for Patients with CLL or SLL

The FDA has approved the PI3K inhibitor duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...

FDA Approves NGS-Based Test for Patients With ALL or MM

The FDA authorized the next-generation sequencing (NGS)–based ClonoSEQ assay for the measurement of minimal residual disease (MRD) in patients with acute lymphocytic leukemia (ALL)...

U.K. Panel Rejects Venetoclax-Rituximab Combo for CLL

The U.K.’s National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting the combination of venetoclax and rituximab for the treatment...

Clinical Trials of Leukemia and Lymphoma Drug Placed on Hold

Pharmaceutical manufacturer Affimed has halted two trials of its CD19/CD3-targeting T-cell engager AFM11 following reports of three serious adverse events (AEs), including one patient...

Patient Dies After Developing Resistance to CAR T-Cell Therapy

A young patient with B-cell acute lymphocytic leukemia who received chimeric antigen receptor (CAR) T-cell therapy developed a resistance to his treatment, according to...

European Commission Expands Blinatumomab’s Approval for ALL

The European Commission (EC) has approved an expanded indication for blinatumomab to include the treatment of pediatric patients with Philadelphia chromosome–negative (Ph-negative) relapsed or...

Umbralisib Demonstrates Safety, Efficacy for Patients With Kinase Inhibitor–Intolerant CLL

According to a report presented at the 23rd Congress of the European Hematology Association, the phosphoinositide 3-kinase (PI3K) and casein kinase-1ε inhibitor umbralisib represents...

Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL

The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...

Extended Analysis Shows Venetoclax Continues to Produce Deep Responses in CLL

In 2016, the U.S. Food and Drug Administration granted venetoclax accelerated approval for the treatment of adults with previously treated chronic lymphocytic leukemia (CLL)...

Combining Ibrutinib and Venetoclax Produces High MRD-Negative Rates in Treatment-Naïve CLL

The all-oral regimen of single-agent ibrutinib followed by combined ibrutinib and venetoclax increased the odds that patients with treatment-naïve chronic lymphocytic leukemia (CLL) will...
Advertisement

Current Issue

December 2018, Volume 4, Issue 14

This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.